- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01363089
Study to Assess the PK of Ketorolac Tromethamine Intranasal and to Assess the Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
Open Label, 2-Way Crossover Study to Assess the PK of Intranasal Ketorolac Tromethamine and to Assess the Effects of a Single Dose of Oxymetazoline Hydrochloride on the PK of Intranasal Ketorolac Tromethamine in Healthy Male Subjects
This was an open label, two way crossover study in healthy male subjects. Two treatments were administered to each subject, one treatment per study period, in a randomized manner. Subjects remained resident in the Clinical Unit from the evening of Day 1 until the morning of Day 2 of each period and there was a washout period of at least 2 days between treatments. A post study medical examination was performed prior to discharge in Period 2.
The objective of this study was to assess the effects of a single dose of intranasal oxymetazoline hydrochloride on the pharmacokinetics of intranasal ketorolac in healthy male subjects.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom
- ICON Development Solutions
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject was male and aged 18 to 62 years inclusive
- Male subjects with female partners of child bearing potential must have consented to use a medically acceptable method of contraception (oral or implanted contraceptive hormones, intrauterine device or surgical sterilization plus condom or diaphragm with spermicidal agent) throughout the study period
- Subject had given signed informed consent
- Subject was within 20% of normal weight for his height and body build according to the table of "Desirable Weights for Men and Women" (Metropolitan Life Insurance Co. 1999)
- Subject's medical history was considered normal, with no clinically significant abnormalities
- Subject was considered to be in good health in the opinion of the Investigator, as determined by a pre-study physical examination with no clinically significant abnormalities, vital signs within normal ranges and an electrocardiogram (ECG) with no clinically significant abnormalities
- Subject's pre-study clinical laboratory findings were within normal range or if outside of the normal range were not deemed clinically significant in the opinion of the Investigator
- Subject had bilateral patent nasal airways at screening and Day 1 as assessed by the Investigator
- Subject had a body weight of at least 60 kg
Exclusion Criteria:
- Subject had had a clinically significant illness in the 4 weeks before screening
- Subject used prescribed medications in the 3 weeks prior to dosing or over the counter preparations for 7 days prior to dosing, except paracetamol which was allowed up to 48 hours (h) prior to dosing. Use of multivitamins was permitted
- Subject had a significant history of drug/solvent abuse, or a positive drugs of abuse test at screening
- Subject had a history of alcohol abuse or currently drank in excess of 28 units per week
- Subject currently used tobacco or had a history of smoking within the past 5 years
- Subject was in the opinion of the Investigator not suitable to participate in the study
- Subject had participated in any clinical study with an investigational drug/device within 3 months prior to dosing
- Subject had a positive human immunodeficiency virus (HIV), hepatitis B or hepatitis C screen
- Subject had had a serious adverse reaction or significant hypersensitivity to any drug
- Subject had donated 500 mL or more of blood within the 3 months prior to screening
- Subject had any history of co-existing nasal polyps, NSAID sensitivity and asthma
- Subject had an allergic reaction to aspirin or other NSAIDs
- Subject currently had an upper respiratory tract infection or other respiratory tract condition that could interfere with the absorption of the nasal spray or with the assessment of AEs
- Subject had any suspicion of rhinitis medicamentosa (chronic daily use of topical decongestants)
- Subject had used a monoamine oxidase inhibitor in the 14 days prior to study entry
- Subject had an active peptic ulcer disease, gastrointestinal bleeding or perforation, or a history of peptic ulcer disease or gastrointestinal bleeding
- Subject had anemia due to unexplained or known gastrointestinal bleeding
- Subject had a history of asthma or any other chronic pulmonary disorder
- Subject had renal impairment or a risk of renal failure due to volume depletion
- Subject had a previous history of nasal surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketorolac tromethamine
|
30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
|
Experimental: Oxymetazoline hydrochloride
|
Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (the maximum observed plasma concentration)
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Tmax (the time to maximum concentration)
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
AUC 0-t (the area under the plasma concentration-time curve (AUC) from time zero to the last quantifiable time point post-dose
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
AUCinf (the AUC from time zero to infinity, where possible
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
t1/2z (the terminal half-life, where possible
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
MRT (the mean residence time)
Time Frame: All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Pharmacokinetic analysis by standard model independent methods was performed by a pharmacokineticist using WinNonlin Professional.
Actual blood sampling times for ketorolac assay were converted to a time from dosing (elapsed time).
Elapsed times were listed by subject for each treatment, together with the individual plasma concentrations of ketorolac.
|
All PK parameters were assessed using blood samples collected pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, and 24 hours post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cyril Clarke, BSc MB BS MFPM, ICON Development Solutions
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Respiratory System Agents
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Ketorolac
- Ketorolac Tromethamine
- Phenylephrine
- Oxymetazoline
Other Study ID Numbers
- ROX 2006-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine
-
Singapore Clinical Research InstituteSingapore General Hospital; Duke-NUS Graduate Medical SchoolTerminatedAssess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.Singapore
-
The Touro College and University SystemUniversity of Vienna; Osato Research Institute; University of Mauritius; Mauritius... and other collaboratorsCompletedAssess the Effect of Green Tea on Diabetes | Assess the Effect of Fermented Papaya Pretration on Diabetes | Effects of Green Tea and FPP on C-reactive Proteins | Effects of Green Tea and FPP of Lipid Profiles in Diabetes | Effect of Green Tea and FPP on Atheroma FormationAustria, Mauritius, United States
-
University of the West of ScotlandSwansea UniversityCompletedTo Assess the Impact of the HIT Intervention on Physiological Responses | To Assess the Role of a Secondary High School as a Setting for Promoting Healthy Eating and PA Behaviours | To Determine the Associations Between CVD Risk Factors at Baseline in 15 - 18 Year Old YouthUnited Kingdom
-
Tel-Aviv Sourasky Medical CenterUnknownTo Assess the Beneficial Preemptive and Preventive Effects of PGL on the Immediate and Late (1- and 3 Months) Postoperative Analgesia Requirements
-
International Centre for Diarrhoeal Disease Research...UnknownAssess the Impact of Moringa Leaves on Serum Heamoglobin and Vitamin A Level Among the Adolescent GirlsBangladesh
Clinical Trials on Ketorolac tromethamine
-
Oman Medical Speciality BoardCompletedAcute Renal ColicOman
-
Darnitsa Pharmaceutical CompanyCompleted
-
William Beaumont Army Medical CenterCompletedMusculoskeletal Pain | Analgesia | Adverse EventUnited States
-
Queen's UniversityCompleted
-
Université Catholique de LouvainAnticancer Fund, BelgiumCompletedCurative Breast Cancer Surgery | Inflammatory Positive/Negative Status | Pre Surgical Incision AdministrationBelgium
-
Seattle Children's HospitalUniversity of WashingtonCompletedPostoperative Pain in InfantsUnited States
-
Beth Israel Deaconess Medical CenterSociety for Obstetric Anesthesia and PerinatologyActive, not recruitingPostoperative Pain | Postpartum Hemorrhage | Blood Loss, Postoperative | Analgesia, Obstetrical | Coagulation Defect; Postpartum | Nonsteroidals (NSAIDs)Toxicity | Ketorolac Adverse ReactionUnited States
-
New Mexico Cancer Care AllianceCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerUnited States
-
Egalet LtdCompleted
-
Egalet LtdCompleted